Search
SR-123781A
go.drugbank.com/drugs/DB05361InvestigationalSR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalSponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
AK119
go.drugbank.com/drugs/DB16423InvestigationalAK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
MDL72527
go.drugbank.com/drugs/DB04188ExperimentalCategories: Oxidoreductases Acting on CH-NH Group Donors, antagonists & inhibitorsacetylleucyl-leucyl-norleucinal
go.drugbank.com/drugs/DB07558ExperimentalSynonyms: N-Ac-Leu-leu-norleucinal, N-acetylleucylleucylnorleucinalCategories: NF-kappa B, antagonists & inhibitorsAstaxanthin
go.drugbank.com/drugs/DB06543InvestigationalIt is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment.
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalRozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709Approvedwas developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound at the site from
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigational[L40793] While some patients may remain asymptomatic, typical symptoms of MF arise from abnormalities in blood cell production and may therefore include various cytopenias, infections, splenomegaly, and